Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Aldosterone as a cardiovascular risk factor.

GianPaolo Rossi1, Marco Boscaro, Vanessa Ronconi

  • 1DMCS-Internal Medicine 4, University Hospital, via Giustiniani 2, 35126 Padua, Italy.

Trends in Endocrinology and Metabolism: TEM
|April 6, 2005
PubMed
Summary

Mineralocorticoid receptor (MR) blockade benefits cardiovascular health. MRs in tissues like the heart and vessels can be activated by aldosterone or glucocorticoids, influencing blood pressure.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prospective study of metyrapone in endogenous Cushing's syndrome (PROMPT).

European journal of endocrinology·2025
Same author

Oral Semaglutide in Type 2 Diabetes: Clinical-Metabolic Outcomes and Quality of Life in Real-World Practice.

Journal of clinical medicine·2024
Same author

Clinical and Biochemical Data for the Diagnosis of Endogenous Hypercortisolism: The "Cushingomic" Approach.

The Journal of clinical endocrinology and metabolism·2024
Same author

Comparing ARR Versus Suppressed PRA as Screening Tests for Primary Aldosteronism.

Hypertension (Dallas, Tex. : 1979)·2024
Same author

Consideration in the evaluation of follow-up of resistant hypertension.

Journal of hypertension·2023
Same author

Efficient SARS-CoV-2 infection antagonization by rhACE2 ectodomain multimerized onto the Avidin-Nucleic-Acid-NanoASsembly.

Biomaterials·2023

Area of Science:

  • Cardiovascular Medicine
  • Endocrinology
  • Pharmacology

Background:

  • Aldosterone impacts cardiovascular function via fluid and electrolyte balance, affecting blood volume and pressure.
  • Mineralocorticoid receptors (MR) are present in both epithelial and non-epithelial tissues, including blood vessels and the heart.
  • MR antagonists like spironolactone and eplerenone have demonstrated positive cardiovascular outcomes.

Purpose of the Study:

  • To explore the mechanisms of cardiovascular Mineralocorticoid Receptor (MR) activation.
  • To differentiate MR activation by aldosterone versus glucocorticoids in various cardiovascular conditions.
  • To inform therapeutic strategies for cardiovascular diseases involving MR pathways.

Main Methods:

  • Review of existing literature on aldosterone, Mineralocorticoid Receptors (MR), and cardiovascular effects.

Related Experiment Videos

  • Analysis of conditions with elevated aldosterone (primary aldosteronism) and normal aldosterone (heart failure, hypertension).
  • Consideration of the role of glucocorticoids in MR activation in specific disease contexts.

    • Main Results:

    • Cardiovascular MR activation can be driven by aldosterone, particularly when levels are inappropriately high for salt status.
    • In conditions like heart failure and hypertension, normal aldosterone levels may coexist with MR activation, potentially mediated by glucocorticoids.
    • Tissue damage and reactive oxygen species may contribute to glucocorticoid-mediated MR activation.

    Conclusions:

    • While unilateral adrenalectomy is key for aldosterone-producing adenomas, Mineralocorticoid Receptor (MR) blockade offers a potential therapeutic avenue.
    • MR blockade may be beneficial in cardiovascular diseases characterized by normal aldosterone levels but activated MR pathways.
    • Understanding the dual activation of MR by aldosterone and glucocorticoids is crucial for optimizing cardiovascular disease management.